Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

Sanofi and Regeneron’s Dupixent is already approved to treat eczema in kids as young as 6 years old—and it’s well on its way to becoming a $10 billion drug. Armed with a trial win in even younger ...

Five years after its first FDA approval in eczema, Sanofi’s Dupixent is still blazing a trail in inflammatory diseases. That’s the evaluation of Bill Sibold, Sanofi’s global head of specialty care, ...

Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.

Interview with WNBA legend Diana Taurasi on her battle against eczema and the progress made by WNBA players in the sneaker ...

June 7 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab anti-inflammation drug Dupixent ...

Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, and other inflammatory conditions, it has offered meaningful relief when ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved its blockbuster medicine Dupixent (dupilumab) for a new indication — moderate-to-severe atopic dermatitis (AD) or eczema in ...

Chalk one up for Pfizer’s eczema hopeful—the JAK inhibitor beat placebo at reducing itch and skin inflammation in a third phase 3 study. The drug also posted a slight edge over Sanofi and Regeneron’s ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

Sanofi SNY and partner Regeneron REGN announced positive data from pivotal phase III study evaluating their blockbuster drug, Dupixent (dupilumab), to treat moderate-to-severe atopic dermatitis (“AD”) ...

(Reuters) -The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies ...